Search

everythinglearnresearchcommunity

for

Search:↓

The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.

Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

Finasteride improves prostate cancer detection in PSA test.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.

Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.

The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

Male pattern baldness may predict prostate cancer risk.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

Suppressing certain hormones might help prevent prostate cancer.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.